Getinge (OTCMKTS:GNGBY) Announces Quarterly Earnings Results

Getinge (OTCMKTS:GNGBY) posted its quarterly earnings results on Wednesday. The company reported $0.32 earnings per share (EPS) for the quarter, Zacks reports. Getinge had a return on equity of 11.12% and a net margin of 7.81%.

Getinge Stock Performance

Shares of GNGBY stock opened at $26.23 on Wednesday. The company has a current ratio of 1.31, a quick ratio of 0.74 and a debt-to-equity ratio of 0.26. The firm has a fifty day moving average price of $25.11 and a 200 day moving average price of $22.69. The company has a market cap of $7.14 billion, a P/E ratio of 24.98 and a beta of 0.95. Getinge has a 12 month low of $18.99 and a 12 month high of $26.23.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on GNGBY. UBS Group initiated coverage on Getinge in a research report on Wednesday, September 2nd. They set a “hold” rating for the company. Nordea Equity Research lowered shares of Getinge from a “buy” rating to a “hold” rating in a research note on Monday, August 31st. Pareto Securities cut shares of Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 24th. Finally, Zacks Research cut shares of Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 17th. Four analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

About Getinge

Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support patient care, surgical procedures, infection prevention and the development and production of pharmaceuticals and other medical products.

The company’s portfolio includes equipment for intensive care and cardiovascular procedures, operating-room systems, surgical instruments, sterilization and disinfection solutions, and products used in laboratories and biopharmaceutical manufacturing.